![](https://cdn.sanity.io/images/0vv8moc6/hcplive/1b1575f0ad5b63bc6e0be65b8dd841b0fedd38eb-1737x1818.jpg?fit=crop&auto=format)
Jonathan Barratt, PhD, FRCP: Sparsentan Full FDA Approval, Future IgAN Developments
Among the most active therapeutic pipelines of any rare disease in recent years is that of IgA nephropathy (IgAN), with the latest advancement being the full US Food and Drug Administration (FDA) approval of sparsentan (Filspari) for reducing the loss of …